Genomic Profiling of a Randomized Trial of Interferon-a versus Hydroxyurea in MPN Reveals Mutation-Specific Responses. Blood Adv. 2021 Sep 10.
View in:
PubMed
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. Genome Res. 2021 Aug; 31(8):1381-1394.
View in:
PubMed
Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Blood Adv. 2021 04 13; 5(7):1922-1932.
View in:
PubMed
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9.
View in:
PubMed
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature. 2020 12; 588(7836):157-163.
View in:
PubMed
COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia. 2021 01; 35(1):279-281.
View in:
PubMed
Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis. Blood Adv. 2020 10 13; 4(19):4965-4979.
View in:
PubMed
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
View in:
PubMed
Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN. Front Immunol. 2020; 11:2093.
View in:
PubMed
Murine Models of Myelofibrosis. Cancers (Basel). 2020 Aug 23; 12(9).
View in:
PubMed
Busy signal: platelet-derived growth factor activation in myelofibrosis. Haematologica. 2020 08; 105(8):1988-1990.
View in:
PubMed
Working in the shadows, under the spotlight - Reflections on lessons learnt in the Republic of Ireland after the first 18?months of more liberal Abortion Care. Contraception. 2020 11; 102(5):305-307.
View in:
PubMed
Fedratinib in myelofibrosis. Blood Adv. 2020 04 28; 4(8):1792-1800.
View in:
PubMed
The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harb Perspect Med. 2020 02 03; 10(2).
View in:
PubMed
Both sides now: losses and gains of mutant CALR. Blood. 2020 01 09; 135(2):82-83.
View in:
PubMed
Mutant calreticulin in myeloproliferative neoplasms. Blood. 2019 12 19; 134(25):2242-2248.
View in:
PubMed
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia. 2020 04; 34(4):1075-1089.
View in:
PubMed
The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv. 2018 12 11; 2(23):3428-3442.
View in:
PubMed
JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):110-117.
View in:
PubMed
Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2018 Aug 02; 23(2):308-309.
View in:
PubMed
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436).
View in:
PubMed
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells. J Vis Exp. 2018 01 05; (131).
View in:
PubMed
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018 02 15; 131(7):782-786.
View in:
PubMed
JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018 02; 103(2):e63-e68.
View in:
PubMed
Kinase Inhibitors in the Treatment of Myeloid Malignancies. Hematol Oncol Clin North Am. 2017 08; 31(4):ix-x.
View in:
PubMed
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 08; 31(4):613-626.
View in:
PubMed
Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2017 06 01; 20(6):785-800.e8.
View in:
PubMed
Myeloproliferative neoplasm stem cells. Blood. 2017 03 23; 129(12):1607-1616.
View in:
PubMed
Gain of function in Jak2V617F-positive T-cells. Leukemia. 2017 04; 31(4):1000-1003.
View in:
PubMed
Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms. Pathologe. 2016 Nov; 37(Suppl 2):175-179.
View in:
PubMed
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 09 12; 30(3):404-417.
View in:
PubMed
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr; 6(4):368-81.
View in:
PubMed
RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Rep. 2015 Dec 22; 13(11):2345-2352.
View in:
PubMed
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80.
View in:
PubMed
Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016 Feb; 172(3):412-9.
View in:
PubMed
Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015 Mar 05; 125(10):1548-52.
View in:
PubMed
Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica. 2015 Apr; 100(4):439-51.
View in:
PubMed
Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015 Feb 05; 125(6):1014-24.
View in:
PubMed
How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):268-76.
View in:
PubMed
Hit the spleen, JAK! Blood. 2014 Nov 06; 124(19):2898-900.
View in:
PubMed
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A. 2014 Oct 21; 111(42):15190-5.
View in:
PubMed
Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015 Jan 08; 125(2):327-35.
View in:
PubMed
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014 Oct 13; 26(4):509-20.
View in:
PubMed
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One. 2014; 9(5):e96209.
View in:
PubMed
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014 Apr 07; 211(4):605-12.
View in:
PubMed
Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell. 2013 Sep 05; 13(3):257-8.
View in:
PubMed
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood. 2013 May 02; 121(18):3692-702.
View in:
PubMed
Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J Clin Oncol. 2012 Nov 20; 30(33):4168-70.
View in:
PubMed
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 2012 Sep 06; 489(7414):155-9.
View in:
PubMed
Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am. 2012 Oct; 26(5):1065-81.
View in:
PubMed
miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2013 Feb; 27(2):344-52.
View in:
PubMed
Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012 Jul 05; 120(1):166-72.
View in:
PubMed
EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012 Apr; 26(4):720-7.
View in:
PubMed
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood. 2011 Oct 27; 118(17):4666-73.
View in:
PubMed
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J. 2011 Mar 04; 1:e7.
View in:
PubMed
STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell. 2010 Nov 16; 18(5):405-6.
View in:
PubMed
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011 Mar 03; 117(9):2567-76.
View in:
PubMed
NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res. 2010 Aug 15; 16(16):4074-6.
View in:
PubMed
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010 Jun 15; 17(6):584-96.
View in:
PubMed
CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):e409-11.
View in:
PubMed
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009 Jul 02; 114(1):144-7.
View in:
PubMed
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009 Apr; 41(4):455-9.
View in:
PubMed
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009 May; 23(5):900-4.
View in:
PubMed
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009 May; 23(5):905-11.
View in:
PubMed
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007 Feb 15; 109(4):1355-62.
View in:
PubMed
Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004 Dec; 18(4):227-34.
View in:
PubMed